Xanthomatosis (Familial Hypercholesterolemia) – A Patient‑Friendly Medical Guide

Overview

Xanthomatosis is the clinical term for the presence of cutaneous or tendinous xanthomas—yellowish, cholesterol‑rich deposits—in individuals who have markedly elevated low‑density lipoprotein cholesterol (LDL‑C). When these deposits occur as a manifestation of the inherited disorder familial hypercholesterolemia (FH), the condition is often called “xanthomatosis of familial hypercholesterolemia.”

• What it is: A genetic disorder causing lifelong, severely high LDL‑C that leads to premature atherosclerotic cardiovascular disease (ASCVD) and characteristic cholesterol deposits (xanthomas) in skin, tendons, and sometimes internal organs.
• Who it affects: Both males and females of all ethnicities. Heterozygous FH (HeFH) is far more common than the homozygous form (HoFH).
• Prevalence:
  • HeFH occurs in approximately 1 in 250–300 people worldwide (≈0.4 % of the population) – one of the most common monogenic disorders ^[1].
  • HoFH is rare, affecting roughly 1 in 300,000–400,000 individuals ^[2].
• Why it matters: If untreated, FH shortens life expectancy by 10–30 years because of early‑onset coronary artery disease (CAD), stroke, or peripheral artery disease.

Symptoms

Symptoms arise from two mechanisms: (1) the direct deposition of cholesterol-rich material (xanthomas) and (2) the consequences of persistent high LDL‑C on blood vessels.

Cutaneous and Tendinous Xanthomas

• Skin (eruptive) xanthomas: Small, yellow‑orange papules that may coalesce into plaques, often on the buttocks, shoulders, arms, or legs.
• Tendon xanthomas: Firm, painless, yellowish nodules attached to tendons—most commonly on the Achilles, extensor tendons of the hands, and quadriceps. These are highly specific for FH.
Palmar xanthomas (xanthoma striatum palmaris): Yellow-orange, linear streaks on the thenar and hypothenar eminences of the palms.

Cardiovascular Symptoms

• Chest pain (angina) or discomfort, especially with exertion.
• Shortness of breath on mild activity.
• Palpitations or syncope (may signal arrhythmia or severe ischemia).
• Peripheral claudication (leg pain while walking) in advanced peripheral artery disease.

Other Systemic Findings

• Corneal arcus – a gray‑white ring at the peripheral cornea, common after age 40 in FH but may appear earlier.
• Early‑onset atherosclerotic disease in the carotid arteries (TIA or stroke).
• In HoFH, xanthomas may appear in childhood, sometimes before age 5, and cholesterol levels can exceed 600 mg/dL.

Causes and Risk Factors

Genetic Basis

FH results from pathogenic variants in genes that regulate LDL‑C clearance:

• LDLR – the LDL receptor gene (≈85 % of cases).
• APOB – apolipoprotein B, the ligand for the LDL receptor.
• PCSK9 – gain‑of‑function mutations increase receptor degradation.
• Rarely, mutations in LDLRAP1 cause an autosomal‑recessive form.

Inheritance Patterns

• Autosomal dominant – most HeFH cases; each child has a 50 % chance of inheriting the mutation.
• Autosomal recessive – extremely rare; both parents are carriers.

Non‑Genetic Risk Modifiers

• Unhealthy diet high in saturated fats and trans fats.
• Physical inactivity.
• Obesity, especially visceral adiposity.
• Smoking – accelerates atherosclerosis.
• Co‑existing conditions (e.g., hypothyroidism, nephrotic syndrome) that raise LDL‑C.

Diagnosis

Diagnosis combines clinical evaluation, laboratory testing, and sometimes imaging.

Clinical Criteria

• Dutch Lipid Clinic Network (DLCN) score – assigns points for family history, LDL‑C level, presence of xanthomas, and early ASCVD. A score ≥6 indicates probable or definite FH.
• Simon Broome criteria – uses LDL‑C thresholds, tendon xanthomas, and family history.

Laboratory Tests

• Lipid panel: Fasting LDL‑C >190 mg/dL in adults (or >160 mg/dL with a family history of premature ASCVD) strongly suggests FH.
• ApoB and lipoprotein(a) levels: May be elevated and add to risk assessment.
• Genetic testing: Sequencing of LDLR, APOB, PCSK9, and LDLRAP1 confirms the diagnosis in >80 % of clinically suspected cases. Testing is recommended for the proband and cascade testing of relatives.

Imaging & Ancillary Studies

• Coronary artery calcium (CAC) scoring or CT angiography – to quantify subclinical atherosclerosis.
• Carotid intima‑media thickness (CIMT) ultrasound – early marker of vascular involvement.
• Ultrasound of tendons – helps differentiate tendon xanthomas from other nodules.

Treatment Options

Management aims to lower LDL‑C as much as possible, prevent ASCVD events, and address xanthomas.

Pharmacologic Therapy

• Statins (HMG‑CoA reductase inhibitors) – First‑line. High‑intensity statins (atorvastatin 40–80 mg, rosuvastatin 20–40 mg) can lower LDL‑C by 50–55 %.
• Ezetimibe – Inhibits intestinal cholesterol absorption; adds ~15–20 % LDL‑C reduction when combined with statins.
• PCSK9 inhibitors (evolocumab, alirocumab) – Monoclonal antibodies that reduce LDL‑C by 50–60 % and are especially useful in HeFH not at goal or in HoFH with residual LDL‑R activity.
• Bile‑acid sequestrants (cholestyramine, colesevelam) – Offer modest LDL‑C reductions; useful when statins are not tolerated.
• Lomitapide and Mipomersen – Approved for HoFH; reduce LDL‑C via microsomal triglyceride transfer protein inhibition or antisense inhibition of ApoB, respectively.
• Inclisiran – Small interfering RNA (siRNA) that lowers PCSK9 synthesis; dosing every 6 months after initial loading.

Lipid‑Apheresis

For patients with HoFH or severe HeFH whose LDL‑C remains >200 mg/dL despite maximal medical therapy, therapeutic plasma exchange (LDL‑apheresis) can acutely lower LDL‑C by 50–70 % and is performed every 1–2 weeks.

Lifestyle Interventions

• Heart‑healthy diet – emphasis on fruits, vegetables, whole grains, legumes, nuts, and oily fish; limit saturated fat <7 % of total calories and eliminate trans fats.
• Regular aerobic exercise – at least 150 min/week of moderate‑intensity activity, tailored to cardiovascular tolerance.
• Weight management – aim for BMI < 25 kg/m² unless contraindicated.
• Smoking cessation – counseling, nicotine replacement, or pharmacotherapy.
• Alcohol moderation – no more than 1 drink/day for women, 2 for men.

Management of Xanthomas

• Aggressive LDL‑C lowering often leads to gradual flattening of xanthomas over months to years.
• Surgical excision or laser therapy may be considered for disfiguring lesions, but only after lipid levels are controlled to prevent recurrence.

Living with Xanthomatosis (Familial Hypercholesterolemia)

Successful long‑term control requires a partnership between the patient, family, and healthcare team.

Daily Management Tips

• Medication adherence: Use pillboxes, smartphone reminders, or automatic pharmacy refills.
• Track lipids: Check fasting lipid panel at least annually; more often after medication changes.
• Family screening: Encourage first‑degree relatives to undergo lipid testing and genetic counseling.
• Physical activity logs: Record weekly exercise to stay accountable.
• Nutrition planning: Work with a registered dietitian experienced in lipid disorders.
• Vaccinations: Keep up‑to‑date, especially flu and COVID‑19, as infections can destabilize plaques.
• Psychological support: Visible xanthomas can affect self‑image; counseling or support groups (e.g., FH Foundation) are beneficial.

Monitoring Schedule

Visit Type	Frequency	Key Assessments
Primary care / lipid clinic	Every 3–6 months (initially)	Lipid panel, medication tolerance, blood pressure, weight.
Cardiology	Every 1–2 years (or sooner if symptoms)	ECG, stress test, CAC score.
Imaging for xanthomas	As needed	Ultrasound or MRI if lesions are large or symptomatic.

Prevention

While the genetic defect cannot be undone, the following strategies markedly lower the risk of premature ASCVD.

• Start high‑intensity statin therapy in childhood for confirmed HoFH, or as early as possible for HeFH (often by age 8–10 years).
• Implement population‑wide cholesterol screening: universal lipid panel at ages 9–11 and again at 17–21 per AHA/ACC guidelines.
• Promote a heart‑healthy diet in schools and families.
• Encourage regular physical activity from childhood.
• Educate about the importance of cascade genetic testing—identifying one case can protect multiple relatives.
• Control co‑existing conditions (diabetes, hypertension, hypothyroidism) aggressively.

Complications

If LDL‑C remains uncontrolled, the following complications are common and can be life‑threatening.

• Coronary artery disease (CAD): Angina, myocardial infarction, heart failure, or sudden cardiac death. Up to 50 % of untreated HeFH patients develop CAD before age 50 %^[3].
• Peripheral artery disease (PAD): Claudication, critical limb ischemia, or gangrene.
• Stroke or transient ischemic attack (TIA): Due to carotid or intracranial atherosclerosis.
• Aortic valve disease: Early calcific aortic stenosis is observed in FH patients.
• Pancreatitis: Rarely, extremely high triglycerides may precipitate pancreatitis.
• Psychosocial impact: Disfigurement from xanthomas can cause anxiety, depression, or social withdrawal.

When to Seek Emergency Care

---

**References**

1. Wierzbicki AS, et al. Familial hypercholesterolemia: a systematic review of prevalence, diagnosis and management. Clin Lipidol. 2019.
2. Mayo Clinic – Homozygous Familial Hypercholesterolemia. Updated 2023.
3. Centers for Disease Control and Prevention – Familial Hypercholesterolemia. Accessed 2024.
4. Nordestgaard BG, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population. Circulation. 2013.
5. Cleveland Clinic – Familial Hypercholesterolemia. Reviewed 2023.